Horizon Discovery Sign Cancer Metabolomics Service Agreement with GlaxoSmithKline
News Oct 29, 2009
Horizon Discovery (Horizon) has announced it has signed a commercial service agreement with Global Pharmaceutical company; GlaxoSmithKline relating to its X-MAN technology.
Horizon’s X-MAN (Mutant And Normal) cell-line technology provides the first genetically-defined and patient-relevant in vitro models of human cancer. These models are being used by a growing number of Pharma and Biotech companies to accelerate and economize the discovery on new ‘targeted’ or ‘personalized’ cancer medicines.
The agreement contributes to the identification and characterization of novel biomarkers, disease signatures and therapeutic targets in the field of cancer ‘metabolomics’; a rapidly growing area of translational cancer research.
“Dr Chris Torrance, CEO of Horizon says “Horizon uses the power of ‘isogenic’ human cancer models to define how tumors in specific cancer patient-populations become dependent on certain nutrient sources and whether they generate unique metabolite signatures that can be secreted into the bloodstream. In this way, we aim to develop early-detection methods and new classes of ‘personalized’ therapeutics that may starve cancers into submission”
About 422 million people around the world, including more than 30 million Americans, have diabetes. Obesity is the most significant risk factor for type 2 diabetes. yet about 30 percent of obese people do not develop type 2 diabetes or other metabolic conditions. New research aims to understand on a cellular level, how this separation occurs.READ MORE
Habitat loss, habitat fragmentation and the loss of genetic diversity are the main factors driving the extinction of many wild species, and the few eastern massasauga rattlesnakes remaining in Illinois have certainly suffered two of the three. A long-term study of these snakes reveals, however, that – despite their alarming decline in numbers – they have retained a surprising amount of genetic diversity.READ MORE